Necrostatin-1 (NEC1) is a receptor-interacting protein kinase-1 (RIPK1)-targeted necroptosis inhibitor that has shown potential therapeutic effects in various skeletal system diseases, including cartilage thinning, osteonecrosis, osteoporosis, and OA (L. Cao and Mu, 2021). The gene discussed is RIPK1; the disease is osteoporosis.